Concepedia

Publication | Closed Access

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

DOI

20

Citations

0

References

2019

Year

Elisa A. Rozeman, Alexander M. Menzies, Oscar Krijgsman, Esmée P. Hoefsmit, Bart A. van de Wiel, Karolina Sikorska, Trieu My Van, Hanna Eriksson, Carolien Bierman, Michel González,
Annals of Oncology

No additional data available for this publication yet. Check back later!